Die kostenlosen ARIVA.DE Börsen-Dienste:
Bleiben Sie immer informiert und melden Sie sich jetzt für die Newsletter von ARIVA.DE an!
Jetzt kostenlos abonnieren

Trader 2018/4: knarf55

Cashbestand:
674,54 €
Platz:
Gesamtwert mit Cash:
33.498,99 € (28.04.20 11:29)
Börsenspiel beendet. Diese Werte werden nicht mehr aktualisiert.
Kurse zum Spielende    

News

Zeit
Titel
Wertpapier
 
07:30 Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin Technologies
08.04.24 Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies
28.02.24 Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Technologies
15.02.24 Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin Technologies
09.02.24 Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Palatin Technologies
05.02.24 Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Technologies
01.02.24 Palatin Announces Closing of $10 Million Registered Direct Offering
Palatin Technologies
30.01.24 Thinking about buying stock in Arcus Biosciences, Palatin Technologies, Exxon Mobil, Archer Aviation, or Sidus Space ?
Palatin Technologies
30.01.24 Palatin Announces $10 Million Registered Direct Offering
Palatin Technologies
08.01.24 Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Palatin Technologies
22.12.23 Thinking about buying stock in Macy's, Mullen Automotive, Lottery.com, Palatin Technologies, or Reviva Pharmaceuticals?
Palatin Technologies
20.12.23 Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Palatin Technologies
18.12.23 Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Palatin Technologies
14.11.23 Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin Technologies
09.11.23 Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
Palatin Technologies
24.10.23 Palatin Announces Closing of $5 Million Registered Direct Offering
Palatin Technologies
23.10.23 Palatin Announces $5 Million Registered Direct Offering
Palatin Technologies
19.10.23 Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
Palatin Technologies
18.10.23 Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Palatin Technologies
16.10.23 Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Palatin Technologies
13.10.23 Palatin Receives Notice of Non-Compliance from NYSE American
Palatin Technologies
28.09.23 Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
Palatin Technologies
22.09.23 Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
Palatin Technologies
07.09.23 Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Palatin Technologies
07.09.23 Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
Palatin Technologies
11.08.23 Thinking about buying stock in Cellebrite DI, Milestone Pharmaceuticals, Palatin Technologies, Limbach Holdings, or Eton Pharmaceuticals?
Palatin Technologies
10.08.23 Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
Palatin Technologies
08.08.23 Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
Palatin Technologies
07.08.23 Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
Palatin Technologies
04.08.23 Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
Palatin Technologies
07:30
Palatin Technologies
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
08.04.24
Palatin Technologies
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
28.02.24
Palatin Technologies
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
15.02.24
Palatin Technologies
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
09.02.24
Palatin Technologies
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
05.02.24
Palatin Technologies
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
01.02.24
Palatin Technologies
Palatin Announces Closing of $10 Million Registered Direct Offering
30.01.24
Palatin Technologies
Thinking about buying stock in Arcus Biosciences, Palatin Technologies, Exxon Mobil, Archer Aviation, or Sidus Space ?
30.01.24
Palatin Technologies
Palatin Announces $10 Million Registered Direct Offering
08.01.24
Palatin Technologies
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
22.12.23
Palatin Technologies
Thinking about buying stock in Macy's, Mullen Automotive, Lottery.com, Palatin Technologies, or Reviva Pharmaceuticals?
20.12.23
Palatin Technologies
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
18.12.23
Palatin Technologies
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
14.11.23
Palatin Technologies
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
09.11.23
Palatin Technologies
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
24.10.23
Palatin Technologies
Palatin Announces Closing of $5 Million Registered Direct Offering
23.10.23
Palatin Technologies
Palatin Announces $5 Million Registered Direct Offering
19.10.23
Palatin Technologies
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
18.10.23
Palatin Technologies
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
16.10.23
Palatin Technologies
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
13.10.23
Palatin Technologies
Palatin Receives Notice of Non-Compliance from NYSE American
28.09.23
Palatin Technologies
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
22.09.23
Palatin Technologies
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
07.09.23
Palatin Technologies
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07.09.23
Palatin Technologies
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
11.08.23
Palatin Technologies
Thinking about buying stock in Cellebrite DI, Milestone Pharmaceuticals, Palatin Technologies, Limbach Holdings, or Eton Pharmaceuticals?
10.08.23
Palatin Technologies
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
08.08.23
Palatin Technologies
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
07.08.23
Palatin Technologies
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
04.08.23
Palatin Technologies
Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
Musterdepot - © Ismagilov / Shutterstock

Das kostenlose Musterdepot von ARIVA.DE

Bei einem niedrigen Kurs einsteigen, bei einem hohen Kurs wieder verkaufen – es klingt einfach, an der Börse Erfolg zu haben. Tatsächlich brauchen Aktionäre gute Nerven, wenn die Kurse auf und ab schwanken. Realistische Anlageziele, eine klare Linie bei der Auswahl der Wertpapiere und das clevere Einsetzen bestimmter Ordertypen gehören zum Handwerk beim Handel mit Wertpapieren.

Um ein Gefühl dafür zu bekommen, welche Strategien in welchen Börsenphasen fruchten, können Nutzerinnen und Nutzer bei ARIVA.DE kostenlos ein Musterdepot anlegen und Wertpapiere wie Anleihen, Aktien, Derivate oder Fonds virtuell im Musterdepot handeln. Die Orders werden zum Schein ausgeführt und finden sich dann in einem virtuellen Musterdepot, ohne dass die Papiere tatsächlich ge- oder verkauft werden. So lassen sich Anlagestrategien testen, ohne Geld zu riskieren.

Viele Nutzer bauen auf ARIVA.DE im Musterdepot ihr reales Depot nach, das ein Broker für sie führt. Grund: Beim Musterdepot auf ARIVA.DE ist jede Position mit den zugehörigen News, dem Forum und der Profilseite verlinkt. Über die Aktien auf dem Laufenden zu bleiben, ist durch das Musterdepot sehr einfach. Möglich ist es auf ARIVA.DE auch, interessante Wertpapiere in eine Watchlist aufzunehmen, um ihre Entwicklung im Auge zu behalten. Nutzer können dabei Kursgrenzen vorgeben und sich bei Erreichen benachrichtigen lassen.

Übrigens: Wer ein virtuelles Musterdepot im Rahmen eines der Börsenspiele von ARIVA.DE eröffnet, hat einen weiteren Lerneffekt: Beim Börsenspiel wird ein Budget vorgegeben, und für jede Transaktion fallen virtuelle Gebühren an. Das macht den „Scheinhandel“ noch realistischer.